Population-Scale Multiome Immune Cell Atlas Reveals Complex Disease Drivers

Published in this week’s literature, researchers from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and international institutions have released a population-scale immune multiome atlas. Analyzing peripheral blood mononuclear cells from 1,108 Finnish individuals, the study maps millions of genetic variants to gene regulation, providing testable hypotheses for over half of all known immune disease associations.

Mapping Multi-Layered Regulatory Pathways in Human Immune Cells

Most genetic variants associated with complex immune-mediated diseases reside in non-coding regions of the human genome. Traditionally, connecting these non-coding sequences to actual biological function has presented a major hurdle for clinical researchers. To bridge this gap, the research consortium generated paired single-nucleus ATAC-seq (assay for transposase-accessible chromatin using sequencing) and RNA-seq (ribonucleic acid sequencing) profiles.

This dual approach allowed investigators to measure chromatin accessibility—how tightly wound DNA is packaged—alongside active gene expression within the same individual cells. By scaling this technology across 1,108 donors from the FinnGen study and the Finnish Red Cross Blood Service, the team identified 51,083 cis-eQTLs (expression quantitative trait loci) for 20,829 genes and 338,100 cis-caQTLs (chromatin accessibility quantitative trait loci) for 210,584 peaks. The atlas also charts 119,094 fine-mapped variants and 496,488 enhancer-gene links, establishing a comprehensive map of how genetic architecture governs immune cell behavior.

In Plain English: The Clinical Takeaway

• Connecting Genes to Disease: The atlas links hidden DNA switches in immune cells to the actual genes they control, helping researchers understand the root causes of autoimmune and inflammatory conditions.
• The Power of Scale: By analyzing cells from a cohort of individuals using advanced simultaneous single-cell sequencing, the study captured rare genetic variations unique to isolated populations like the Finnish cohort.
• Experimental Validation: Scientists utilized cutting-edge base editing tools to prove that specific flagged DNA variants directly drive immune disease mechanisms, particularly at Finnish-enriched loci such as TNRC18.

Unraveling Regulatory Buffering and Evolutionarily Constrained Genes

A critical discovery within the atlas involves how the human genome protects evolutionarily constrained genes—those vital genes that tolerate very little genetic mutation over evolutionary time.

The new single-cell multiome data reveals a more nuanced reality: multi-layered regulatory buffering. While chromatin accessibility changes at these loci occur with normal effect sizes, the transmission signal to final gene expression is systematically attenuated through weaker enhancer-gene links. This buffering mechanism explains why disease-associated variants can still target evolutionarily constrained genes without triggering lethal expression changes, reconciling a long-standing paradox in human genetics.

Systematic classification of these regulatory pathways demonstrated that variants exhibiting a complete chromatin-to-expression cascade show twice the disease colocalization rate of chromatin-only effects. This establishes a clear biological hierarchy where tracking the full mechanistic cascade successfully predicts disease relevance. To confirm causality, the team incorporated base editing experiments directly validating functional mechanisms at disease loci enriched in the Finnish population.

Summary of Multiome Atlas Genomic Metrics

Metric Category	Quantified Count	Target Biological Feature
Single-Nucleus Profiles	Peripheral blood mononuclear cells (PBMCs)	Peripheral blood mononuclear cells (PBMCs)
Cohort Size	1,108 individuals	Finnish biobank donors (FinnGen / Red Cross)
cis-eQTLs	51,083	Genetic variants linked to gene expression across 20,829 genes
cis-caQTLs	338,100	Genetic variants linked to chromatin accessibility across 210,584 peaks
Fine-Mapped Variants	119,094	Statistically refined causal variants
Enhancer-Gene Links	496,488	Regulatory connections between distal DNA elements and target genes

Funding Transparency and Global Research Collaboration

This large-scale investigation was supported by institutional funding from the Klarman Cell Observatory and departmental funds from the Department of Molecular Biology at Massachusetts General Hospital, alongside support from the Masason Foundation. Sample collection and cohort profiling were enabled by blood donors and staff at the Finnish Red Cross Blood Service, as well as participants and investigators of the FinnGen study, which is funded by Business Finland and multiple biopharmaceutical industry partners including AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, and Bayer. Several authors declare competing financial interests as co-founders, board directors, or scientific advisors for biotechnology firms such as Convergence Bio, MoonLake Immunotherapeutics, and Maze Therapeutics, as detailed in the primary repository disclosures.

Translating Molecular Atlases into Targeted Therapeutics

The publication of this population-scale immune multiome atlas marks a shift from descriptive genetics to functional mechanistic interpretation. By providing testable hypotheses for over half of all known immune disease associations, the dataset equips drug developers and clinical researchers with the high-resolution maps necessary to design targeted therapies.

References

• Kanai, M., Delorey, T.M., Honkanen, J. et al. Population-scale multiome immune cell atlas reveals complex disease drivers. medRxiv (Preprint). DOI: 10.1101/2025.11.25.25340489.
• FinnGen Study. Business Finland grants HUS 4685/31/2016 and UH 4386/31/2016.